ITCI - Intra-Cellular Therapies Inc Stock Price, Fair Value and News

65.00USD-1.53 (-2.30%)Market Closed

Market Summary

USD65.00-1.53

Market Closed

-2.30%

ITCI Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

ITCI Stock Price

View Fullscreen

ITCI RSI Chart

ITCI Valuation

Market Cap

6.9B

Price/Earnings (Trailing)

-61.9

Price/Sales (Trailing)

13.35

EV/EBITDA

-61.46

Price/Free Cashflow

-69.66

ITCI Price/Sales (Trailing)

ITCI Profitability

EBT Margin

-21.38%

Return on Equity

-18.49%

Return on Assets

-14.84%

Free Cashflow Yield

-1.44%

ITCI Fundamentals

ITCI Revenue

Revenue (TTM)

513.9M

Rev. Growth (Yr)

52%

Rev. Growth (Qtr)

9.66%

ITCI Earnings

Earnings (TTM)

-110.9M

Earnings Growth (Yr)

65.39%

Earnings Growth (Qtr)

46.65%

Breaking Down ITCI Revenue

Last 7 days

0.1%

Last 30 days

-15.2%

Last 90 days

-14.1%

Trailing 12 Months

3.2%

How does ITCI drawdown profile look like?

ITCI Financial Health

Current Ratio

5.12

ITCI Investor Care

Shares Dilution (1Y)

10.06%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	513.9M	0	0	0
2023	310.6M	365.8M	420.1M	464.4M
2022	102.9M	138.5M	188.1M	250.3M
2021	37.6M	55.7M	70.6M	83.8M
2020	9.3M	13.8M	18.3M	22.8M
2019	0	0	0	4.8M
2017	426.0K	312.3K	338.7K	245.8K
2016	0	316.5K	263.5K	361.4K
2015	0	466.9K	247.7K	153.9K
2014	2.3M	1.9M	1.3M	577.3K
2013	3.1M	2.3M	2.6M	2.7M
2012	0	16.6M	9.9M	3.1M
2011	0	0	0	23.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Intra-Cellular Therapies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 24, 2024	mates sharon	acquired	345,618	17.2637	20,020	chairman and ceo
Mar 31, 2024	van nostrand robert l	acquired	5,466	69.2	79.00	-
Mar 31, 2024	riggs rory b	acquired	17,992	69.2	260	-
Mar 20, 2024	riggs rory b	acquired	371,200	18.56	20,000	-
Mar 11, 2024	mates sharon	sold	-1,341,120	65.2139	-20,565	chairman, president & ceo
Mar 11, 2024	hineline lawrence j.	sold	-667,587	65.9606	-10,121	svp of finance, cfo
Mar 11, 2024	neumann mark	sold	-481,931	65.6135	-7,345	evp, chief commercial officer
Mar 11, 2024	halstead michael	sold	-484,537	65.9683	-7,345	evp and general counsel
Mar 11, 2024	durgam suresh k.	sold	-243,482	65.5933	-3,712	evp, chief medical officer
Mar 10, 2024	halstead michael	acquired	-	-	7,345	evp and general counsel

Which funds bought or sold ITCI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-68.49	-8,314,740	3,639,780	-%
May 16, 2024	COMERICA BANK	added	0.6	-10,093	348,853	-%
May 16, 2024	Arete Wealth Advisors, LLC	reduced	-0.17	-65,068	1,772,560	0.16%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.98	-542,464	6,078,800	0.01%
May 16, 2024	Creekmur Asset Management LLC	unchanged	-	-121	3,460	-%
May 16, 2024	Jaffetilchin Investment Partners, LLC	reduced	-1.8	-20,342	376,863	0.03%
May 16, 2024	CASTLEARK MANAGEMENT LLC	reduced	-26.52	-1,532,840	3,752,720	0.16%
May 16, 2024	Tidal Investments LLC	added	13.85	23,280	255,902	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-66.29	-962,356	464,816	-%
May 15, 2024	HighVista Strategies LLC	added	154	1,000,510	1,684,120	0.60%

Are Funds Buying or Selling ITCI?

Are funds buying ITCI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ITCI

No. of Funds

Unveiling Intra-Cellular Therapies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.45%	9,094,302	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	1.83%	1,763,475	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	8,192,987	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.78%	8,319,249	SC 13G/A
Feb 06, 2023	wellington management group llp	5.71%	5,409,685	SC 13G
Feb 03, 2023	blackrock inc.	7.9%	7,449,529	SC 13G/A
Jan 10, 2023	wasatch advisors inc	-	0	SC 13G/A

Recent SEC filings of Intra-Cellular Therapies Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 25, 2024	4	Insider Trading
Apr 24, 2024	8-K	Current Report
Apr 18, 2024	424B5	Prospectus Filed
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	424B5	Prospectus Filed

Peers (Alternatives to Intra-Cellular Therapies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Intra-Cellular Therapies Inc News

Latest updates

Intra-Cellular Therapies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q4	2017Q3	2017Q2
Revenue	9.7%	144,866,000	132,099,000	126,173,000	110,792,000	95,306,000	87,869,000	71,870,000	55,579,000	34,996,000	25,671,000	22,207,000	20,047,000	15,878,000	12,454,291	7,368,594	1,906,636	1,083,479	544,267	5,055	30,754	114,741
Operating Expenses	-0.2%	165,818,000	166,196,000	155,886,000	157,971,000	143,698,000	135,281,000	127,499,000	143,502,000	107,658,000	111,675,000	99,531,000	89,188,000	69,097,000	73,787,606	63,305,048	66,778,953	50,169,003	41,829,272	-	-	-
S&GA Expenses	-100.0%	-	104,720,000	105,207,000	101,014,000	98,923,000	94,631,000	88,375,000	100,316,000	75,460,000	79,678,000	70,498,000	69,851,000	52,584,000	58,348,504	52,473,573	41,445,557	34,096,366	22,763,547	-	-	-
R&D Expenses	-15.6%	42,833,000	50,774,000	41,550,000	49,794,000	38,024,000	33,862,000	33,274,000	38,536,000	29,043,000	29,458,000	27,032,000	17,297,000	15,058,000	14,298,449	10,275,368	25,204,857	16,003,326	19,065,726	-	-	-
EBITDA Margin	28.7%	-0.21	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.94	-3.38	-3.66	-4.25	-	-	-	-	-	-	-	-	-
Income Taxes	-19.9%	359,000	448,000	43,000	135,000	10,000	-	1,000	-	5,000	6,000	23,000	-24,000	-5,000	-10,232	-	-	-3,281	-	-	-	-
Earnings Before Taxes	47.1%	-14,888,000	-28,131,000	-24,215,000	-42,649,000	-44,043,000	-44,026,000	-53,507,000	-86,603,000	-72,114,000	-85,734,000	-76,931,000	-68,720,000	-52,735,000	-60,688,796	-55,183,625	-63,712,258	-47,407,321	-40,582,851	-	-	-
EBT Margin	28.6%	-0.21	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.95	-3.39	-3.67	-4.26	-	-	-	-	-	-	-	-	-
Net Income	46.6%	-15,247,000	-28,579,000	-24,258,000	-42,784,000	-44,053,000	-44,026,000	-53,508,000	-86,603,000	-72,119,000	-85,734,000	-76,908,000	-68,744,000	-52,740,000	-60,699,178	-55,183,625	-63,712,258	-47,410,602	-40,582,851	-	-	-
Net Income Margin	28.3%	-0.22	-0.30	-0.37	-0.50	-0.73	-1.02	-1.58	-2.32	-2.95	-3.39	-3.67	-4.26	-	-	-	-	-	-	-	-	-
Free Cashflow	-1554.6%	-34,117,000	-2,062,000	-25,538,000	-36,802,000	-60,066,000	-39,165,000	-53,468,000	-94,916,000	-83,415,000	-73,185,000	-79,576,000	-59,341,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.6%	747	728	718	714	722	755	782	812	869	490	557	626	674	717	771	441	481	251	281	310	343
Current Assets	3.4%	691	668	702	698	706	738	760	789	848	467	533	601	649	691	745	419	461	230	259	288	321
Cash Equivalents	-4.2%	142	148	99.00	142	76.00	149	135	77.00	129	92.00	106	121	130	61.00	301	129	180	108	102	92.00	64.00
Inventory	36.9%	16.00	12.00	43.00	42.00	28.00	24.00	24.00	25.00	8.00	8.00	8.00	8.00	8.00	7.00	3.00	2.00	1.00	-	-	-	-
Net PPE	-8.0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
Liabilities	7.8%	148	137	117	107	95.00	99.00	97.00	90.00	76.00	72.00	70.00	72.00	62.00	60.00	62.00	61.00	51.00	56.00	54.00	53.00	54.00
Current Liabilities	9.1%	135	124	103	92.00	80.00	83.00	77.00	71.00	59.00	53.00	50.00	50.00	40.00	37.00	38.00	40.00	31.00	36.00	33.00	33.00	33.00
Shareholder's Equity	1.4%	599	591	601	607	628	656	685	722	793	418	487	554	612	657	709	380	430	195	227	257	289
Retained Earnings	-0.9%	-1,632	-1,617	-1,588	-1,564	-1,521	-1,477	-1,433	-1,379	-1,293	-1,221	-1,135	-1,058	-989	-937	-876	-821	-757	-710	-669	-634	-597
Additional Paid-In Capital	1.1%	2,232	2,208	2,191	2,174	2,152	2,138	2,124	2,107	2,089	1,639	1,622	1,612	1,602	1,593	1,585	1,200	1,188	905	896	891	886
Shares Outstanding	1.1%	97.00	96.00	96.00	96.00	96.00	95.00	94.00	94.00	93.00	81.00	81.00	81.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	6,000	-	-	-	-	-	-	-	5,300	-	-	-	3,200	-	-	-	614	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1555.3%	-34,116	-2,061	-25,270	-36,802	-60,066	-39,193	-53,351	-94,793	-82,849	-73,184	-79,267	-59,326	-47,767	-68,242	-63,579	-47,024	-51,226	-35,055	-29,989	-27,308	-35,629
Share Based Compensation	-6.8%	13,843	14,856	14,311	13,226	10,439	11,159	11,751	11,998	8,105	9,378	9,530	8,617	6,778	4,763	6,901	6,947	5,504	5,939	4,807	4,987	5,055
Cashflow From Investing	-65.9%	16,179	47,422	-20,167	94,748	-16,462	50,263	106,170	37,229	-322,035	51,509	63,772	48,794	116,269	-176,335	-143,216	-7,757	-152,984	37,737	40,237	54,722	44,742
Cashflow From Financing	232.5%	9,989	3,004	2,581	8,585	3,640	2,187	5,654	5,504	441,814	7,914	591	1,582	1,432	3,635	378,494	4,480	277,567	2,793	152	259	31.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ITCI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues, net	$ 144,866	$ 95,306
Operating expenses:
Cost of product sales	9,900	6,751
Selling, general and administrative	113,085	98,923
Research and development	42,833	38,024
Total operating expenses	165,818	143,698
Loss from operations	(20,952)	(48,392)
Interest income	6,064	4,349
Loss before provision for income taxes	(14,888)	(44,043)
Income tax expense	(359)	(10)
Net loss	$ (15,247)	$ (44,053)
Net loss per common share:
Basic (in dollars per share)	$ (0.16)	$ (0.46)
Diluted (in dollars per share)	$ (0.16)	$ (0.46)
Weighted average number of common shares:
Basic (in shares)	96,875,275	95,134,694
Diluted (in share)	96,875,275	95,134,694
Product sales, net
Total revenues, net	$ 144,843	$ 94,731
Grant revenue
Total revenues, net	$ 23	$ 575

ITCI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 139,819	$ 147,767
Investment securities, available-for-sale	335,804	350,174
Restricted cash	1,750	1,750
Accounts receivable, net	131,157	114,018
Inventory	15,949	11,647
Prepaid expenses and other current assets	66,048	42,443
Total current assets	690,527	667,799
Property and equipment, net	1,522	1,654
Right of use assets, net	12,481	12,928
Inventory, non-current	34,818	38,621
Other assets	7,688	7,293
Total assets	747,036	728,295
Current liabilities:
Accounts payable	11,532	11,452
Accrued and other current liabilities	33,249	27,944
Accrued customer programs	69,972	53,173
Accrued employee benefits	16,409	27,364
Operating lease liabilities	3,639	3,612
Total current liabilities	134,801	123,545
Operating lease liabilities, non-current	12,737	13,326
Total liabilities	147,538	136,871
Stockholders’ equity:
Common stock, $0.0001 par value: $175,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; $97,477,818 and $96,379,811 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10	10
Additional paid-in capital	2,232,325	2,208,470
Accumulated deficit	(1,632,407)	(1,617,160)
Accumulated comprehensive (loss) income	(430)	104
Total stockholders’ equity	599,498	591,424
Total liabilities and stockholders’ equity	$ 747,036	$ 728,295

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

CEO	Dr. Sharon Mates Ph.D.
WEBSITE	intracellulartherapies.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	561

Intra-Cellular Therapies Inc Frequently Asked Questions

What is the ticker symbol for Intra-Cellular Therapies Inc? What does ITCI stand for in stocks?

ITCI is the stock ticker symbol of Intra-Cellular Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intra-Cellular Therapies Inc (ITCI)?

As of Fri May 17 2024, market cap of Intra-Cellular Therapies Inc is 6.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers.

What is the fair value of ITCI stock?

You can check ITCI's fair value in chart for subscribers. The fair value of Intra-Cellular Therapies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intra-Cellular Therapies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITCI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intra-Cellular Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether ITCI is over valued or under valued. Whether Intra-Cellular Therapies Inc is cheap or expensive depends on the assumptions which impact Intra-Cellular Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITCI.

What is Intra-Cellular Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ITCI's PE ratio (Price to Earnings) is -61.9 and Price to Sales (PS) ratio is 13.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITCI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intra-Cellular Therapies Inc's stock?

In the past 10 years, Intra-Cellular Therapies Inc has provided 0.158 (multiply by 100 for percentage) rate of return.